Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women

被引:1
|
作者
Luengratsameerung, S. [1 ]
Panyakhamlerd, K. [1 ]
Treratanachat, S. [2 ]
Taechakraichana, N. [1 ]
机构
[1] Chulalongkorn Univ, Reprod Med Div, Dept Obstet & Gynecol, Menopause Res Unit,Fac Med, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Div Gynecol Pathol, Dept Obstet & Gynecol, Fac Med, Bangkok 10330, Thailand
关键词
CONJUGATED EQUINE ESTROGEN; VAGINAL CREAM; BONE TURNOVER MARKERS; POSTMENOPAUSE; VULVOVAGINAL ATROPHY; HORMONE REPLACEMENT THERAPY; BIOCHEMICAL MARKERS; MINERAL DENSITY; LOCAL ESTROGEN; ESTRADIOL; EFFICACY; CALCIUM; 17-BETA-ESTRADIOL; RALOXIFENE; MANAGEMENT;
D O I
10.3109/13697137.2012.662252
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the systemic effect of therapy with conjugated equine estrogen (CEE) vaginal cream on bone turnover markers in postmenopausal women. Methods This study was conducted in 40 spontaneously menopausal women aged 40-60 years who complained of vulvovaginal symptoms. Subjects were instructed to self-administer 1 g CEE vaginal cream (CEE 0.625 mg) once daily for 12 weeks (continuous phase), then twice weekly for the next 12 consecutive weeks (intermittent phase). Serum levels of bone turnover markers and estradiol and the vaginal maturation index were evaluated at baseline, 12 and 24 weeks after treatment initiation. Results Levels of C-terminal cross-linked telopeptide of type I collagen (CTx) were significantly decreased at 12 weeks and 24 weeks when compared to baseline values (median (range) 0.435 (0.171-0.859) and 0.391 (0.122-0.714) vs. 0.562 (0.250-1.290) ng/ml (p < 0.001 and < 0.001), respectively), but there was no significant difference between the levels at 12 and 24 weeks. Levels of procollagen type I N-terminal propeptide (P1NP) and osteocalcin levels were significantly decreased after 24 weeks when compared to pretreatment levels (mean (standard deviation) 41.74 (11.76) vs. 50.02 (17.71) ng/ml (p = 0.002) for P1NP and 23.91 (7.11) vs. 27.54 (8.67) ng/ml (p < 0.001) for osteocalcin, respectively). Estradiol levels were significantly increased and the vaginal maturation index was significantly improved after 12 and 24 weeks when compared to baseline. Conclusions CEE vaginal cream significantly decreased the bone resorption marker (CTx) in postmenopausal women after completion of the continuous-treatment phase. There was no significant further decrease after the intermittent phase. The effects on the markers of bone formation and bone turnover (P1NP and osteocalcin) were apparent only at 24 weeks. The two treatment phases moderately increased serum estradiol levels and significantly improved the vaginal maturation index.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
  • [31] Effects of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis
    Johnell, O
    Lu, Y
    Seeman, E
    Reginster, J
    Scheele, W
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S184 - S184
  • [32] Bone turnover markers do not identify bone status in postmenopausal women
    Muñoz-Torres, M
    Mezquita-Raya, P
    López-Rodríguez, F
    Escobar-Jiménez, F
    BONE, 2001, 28 (05) : S178 - S178
  • [33] Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women
    Smith, Nicholas L.
    Heckbert, Susan R.
    Lemaitre, Rozenn N.
    Reiner, Alexander P.
    Lumley, Thomas
    Rosendaal, Frits R.
    Psaty, Bruce M.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (12) : 2807 - 2812
  • [34] Effect of norethindrone acetate on hormone levels and markers of bone turnover in estrogen-treated postmenopausal women
    Onobrakpeya, OA
    Fall, PM
    Willard, A
    Chakravarthi, P
    Hansen, A
    Raisz, LG
    ENDOCRINE RESEARCH, 2001, 27 (04) : 473 - 480
  • [35] Short-term effects of a new synthetic conjugated estrogens (Cenestin) on biochemical markers of bone turnover in early postmenopausal women
    Garnero, P
    Stevens, RE
    Ayres, SA
    Phelps, KV
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S63 - S63
  • [36] Effects of Denosumab on Bone Turnover Markers in Postmenopausal Osteoporosis
    Eastell, Richard
    Christiansen, Claus
    Grauer, Andreas
    Kutilek, Stepan
    Libanati, Cesar
    McClung, Michael R.
    Reid, Ian R.
    Resch, Heinrich
    Siris, Ethel
    Uebelhart, Daniel
    Wang, Andrea
    Weryha, Georges
    Cummings, Steve R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (03) : 530 - 537
  • [37] Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women
    Yasui, Toshiyuki
    Uemura, Hirokazu
    Tomita, Junko
    Umino, Yuka
    Yamada, Masayo
    Kuwahara, Akira
    Matsuzaki, Toshiya
    Maegawa, Masahiko
    Miura, Masakazu
    Irahara, Minoru
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (04): : 651 - 659
  • [38] The gut microbiome is associated with bone turnover markers in postmenopausal women
    Chen, Lin
    Yan, Shuai
    Yang, Ming
    Yu, Fudong
    Wang, Jingjing
    Wang, Xiaoxin
    Xu, Huanbai
    Shi, Jianxia
    Pan, Ling
    Zeng, Yuexi
    Li, Siyu
    Li, Li
    You, Li
    Peng, Yongde
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (11): : 12601 - 12613
  • [39] Endotoxin and bone turnover markers in postmenopausal women with and without osteoporosis
    Aziz, Ibrahim
    Yakout, Sobhy M.
    Aljohani, Naji
    Al-Saleh, Yousef
    Al-Attas, Omar S.
    Alokail, Majed S.
    Amer, Osama E.
    Sheshah, Eman
    McTernan, Philip G.
    Al-Daghri, Nasser M.
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (10): : 10682 - 10687
  • [40] Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women
    Komi, J
    Heikkinen, J
    Rutanen, EM
    Halonen, K
    Lammintausta, R
    Yikorkala, O
    GYNECOLOGICAL ENDOCRINOLOGY, 2004, 18 (03) : 152 - 158